Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gin Hwa BiotechROCO:7806 22 Gross Margin % is 26.81% as of Dec. 2025, which is 21% below its 10-year median of 33.77. GuruFocus rates ROCO:7806 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 733 Biotechnology companies, Gin Hwa Biotech ranks worse than 75.72% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Gin Hwa Biotech had a gross margin of 26.81% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Gin Hwa Biotech Gross Margin % Related Terms
Gin Hwa Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Gin Hwa Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7806 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Gin Hwa Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gin Hwa Biotech Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gin Hwa Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Gin Hwa Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Gin Hwa Biotech (ROCO:7806) has a Gross Margin % of 26.81% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Gin Hwa Biotech and its competitors. This is 21% below median its historical median of 33.77. Over the past decade, Gin Hwa Biotech's Gross Margin % has ranged from 30.40 to 37.43. According to the industry distribution chart, Gin Hwa Biotech ranks #555 out of 733 companies in the Biotechnology industry, placing it in the top 75.7%.
Is Gin Hwa Biotech's Gross Margin % too high?
Gin Hwa Biotech's current Gross Margin % of 26.81% is 21% below median its 10-year median of 33.77. Over the past 10 years, this metric has ranged from a low of 30.40 to a high of 37.43. The Biotechnology industry median Gross Margin % is 60.91. Gin Hwa Biotech's value of 26.81% is 56% below this industry median. Based on the distribution chart, Gin Hwa Biotech ranks #555 out of 733 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gin Hwa Biotech has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Gin Hwa Biotech's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gin Hwa Biotech ranks #555 out of 733 companies for Gross Margin %. This places Gin Hwa Biotech in the lower half of its industry. The industry median Gross Margin % is 60.91. Gin Hwa Biotech's value of 26.81% is 56% below this benchmark. Historically, Gin Hwa Biotech's own Gross Margin % has ranged from 30.40 to 37.43 over the past decade. While the company's 10-year median is 33.77 vs. the industry median of 60.91, Gin Hwa Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gin Hwa Biotech's current Gross Margin % of 26.81% is 56% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Gin Hwa Biotech and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gin Hwa Biotech's current Gross Margin % is 26.81%, which is 21% below median its own 10-year median of 33.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gin Hwa Biotech stock overvalued right now?
Gin Hwa Biotech (ROCO:7806) has a current Gross Margin % of 26.81%. The current Gross Margin % is 26.81%, which is 21% below median its 10-year median of 33.77 and 56% below the Biotechnology industry median of 60.91. Gin Hwa Biotech's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Gin Hwa Biotech (ROCO:7806), the current Gross Margin % is 26.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gin Hwa Biotech Inc is engaged in developing completely original products to achieve every vision. Its Services and technology are Product Development, OEM Service, Core Technology, R & D Center, Professional Production, and Others.
22GF Score
Get the complete analysis for ROCO:7806
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7806 has been successfully added to your 
